Australia markets closed

Cytokinetics, Incorporated (CYTK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
35.77-1.12 (-3.04%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close36.89
Bid0.00 x 800
Ask0.00 x 1000
Day's range35.19 - 37.05
52-week range14.89 - 39.46
Avg. volume1,897,959
Market cap2.987B
Beta (5Y monthly)1.31
PE ratio (TTM)N/A
EPS (TTM)-2.21
Earnings date02 Nov 2021 - 08 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est50.36
  • Zacks

    How Much Upside is Left in Cytokinetics (CYTK)? Wall Street Analysts Think 37%

    The average of price targets set by Wall Street analysts indicates a potential upside of 36.8% in Cytokinetics (CYTK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

  • GlobeNewswire

    Cytokinetics Outlines Go-To-Market Strategy for Omecamtiv Mecarbil and Provides Updates on Cardiovascular Pipeline at Today’s Analyst & Investor Day

    SEQUOIA-HCM: Phase 3 Trial Design Design of SEQUOIA-HCM, a Phase 3 randomized, placebo-controlled, double-blind, multi-center clinical trial designed to evaluate aficamten in patients with symptomatic oHCM on background medical therapy for 24 weeks. Go-To-Market Strategy Focuses on Educating Healthcare Professionals, Ensuring Managed Care Access, and Enacting Programs for Patient Access, Education and Support Clinical Trial Design Announced for SEQUOIA-HCM, Phase 3 Clinical Trial of Aficamten Ex

  • GlobeNewswire

    Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 30, 2021 it granted stock options to purchase an aggregate of 206,300 shares of common stock to 14 new employees, whose employment commenced in September 2021, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $ 35.74 per share, which is equal to the closing price of the Company’s common stoc